Intraesophageal pH &bilirubin in GERD on gastric acid suppression therapy
$0M01FY2000RRNIH
Temple University, Philadelphia PA
Investigators
Linked publications & trials
Paper 30137555Paper 20194829Paper 17949927Paper 17120297Paper 17071216Paper 16961692Paper 16868831Paper 16768601Paper 16720337Paper 16457777Paper 16416175Paper 16272292Paper 15932362Paper 15916622Paper 15800559Paper 15767618Paper 15235061Paper 15107299Paper 15104362Paper 15086868Paper 15056089Paper 14720034Paper 14717972Paper 14624413Paper 12962693Paper 12866995Paper 12832307Paper 12757160Paper 12660140Paper 12546685Paper 12141833Paper 12135014Paper 12034027Paper 12028371Paper 11768254Paper 11743243Paper 11323422Paper 11270790Paper 11270782Paper 11181007Paper 11051357Paper 11007121Paper 10898747Paper 10644487
Abstract
The objective of this study is to determine if acid or bile reflux into the esophagus is responsible for refractory symptoms of gastroesophageal reflux disease (GERD) despite gastric acid suppressant therapy, including histamine type-2 receptor antagonists (H2RA) or proton pump inhibitors (PPI). This will be determined by simultaneously monitoring, over a 24 hour period, both esophageal pH and bilirubin concentrations in patients with GERD and to allow us to determine if acid reflux, bile refulux, both or neither is responsible.
View original record on NIH RePORTER →